Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1136-1141

  De Denus, Simon ^a,b   Al Jazairi, Abdulrazaq ^c,d   Loh, Evan ^e,f   Jessup, Mariell ^e   Stanek, Eric J ^c,g   Spinler, Sarah A ^a,e  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f PFIZER INC   (United States)

^g Kos Pharmaceuticals Inc   (United States)

Author keywords

Dyslipidemia; Heart transplant; HMG CoA reductase inhibitor

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOPATHY; POSTOPERATIVE CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

CHOLESTEROL, LDL; DRUG UTILIZATION; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 3042634816     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D535     Document Type: Review

References (25)

1. Aranda JM Jr, Hill J. Cardiac transplant vasculopathy. Chest 2000;118: 1792-800.
2. Ross H, Hendry P, Dipchand A, Giannetti N, Hirsch G, Isaac D, et al. 2001 Canadian Cardiovascular Society Consensus Conference on cardiac transplantation. Can J Cardiol 2003;19:620-54. Erratum 2003;19: 958.
3. Valantine H, Rickenbacker P, Kemna M, Hunt S, Chen YD, Reaven G, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001;103:2144-52.
4. Kapadia SR, Nissen SE, Ziada KM, Rincon G, Crowe TD, Boparai N, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 2001;38:206-13.
5. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
6. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.
7. Ballantyne CM. Drugs in cardiac transplantation. N Engl J Med 1996; 334:400-1.
8. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992;19:1315-21.
9. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238-44.
12. LaBresh KA, Owen P, Alteri C, Reilly S, Albright PS, Hordes AR, et al. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. Am J Cardiol 2000;85(suppl 1):23A-9A.
13. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-7.
14. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
15. Brown AS, Cofer LA. Lipid management in a private cardiology practice (the Midwest Heart experience). Am J Cardiol 2000;85(suppl 1): 18A-22A.
16. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
17. Magnani G, Carinci V, Magelli C, Potena L, Reggiani LB, Branzi A. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 2000;19:710-5.
18. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37.
19. Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002;40:1609-14.
20. Kato T, Tokoro T, Namii Y, Kobayashi T, Hayashi S, Yokoyama I, et al. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplant Proc 2000; 32:331-3.
21. Patel DN, Pagani FD, Koelling TM, Dyke DB, Baliga RR, Cody RJ, et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 2002;21:204-10.
22. Package insert. Lipitor (atorvastatin). New York: Pfizer, November 2002.
23. Package insert. Mevacor (lovastatin). Whitehouse Station, NJ: Merck and Co., May 2002.
24. Package insert. Zocor (simvastatin). Whitehouse Station, NJ: Merck and Co., June 2002.
25. Package insert. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers, March 2003.